The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine

Vaccine

Volumn 27, Issue 32, 2009, Pages 4320-4324

  Wu, Fan ^a   Yuan, Xiao Yi ^a   Li, Jing ^a   Chen, Ying Hua ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

CpG ODN; Influenza virus; M2e; Protective activity; Th1 response

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G2A; INFLUENZA M2E VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; DNA; FEMALE; HUMANS; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TH1 CELLS; VACCINES, SUBUNIT;

EID: 67649479249     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.04.075     Document Type: Article

References (19)

1. Subbarao K., Murphy B.R., and Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 24 1 (2006) 5-9
2. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., and Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64 3 (1990) 1375-1377
3. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., and Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5 10 (1999) 1157-1163
4. Liu W., Zou P., and Chen Y.H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 93 2-3 (2004) 131-136
5. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., and Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13 15 (1995) 1399-1402
6. Heinen P.P., Rijsewijk F.A., de Boer-Luijtze E.A., and Bianchi A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 83 Pt 8 (2002) 1851-1859
7. Wu F., Huang J.H., Yuan X.Y., Huang W.S., and Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 25 52 (2007) 8868-8873
8. Wu F., Yuan X.Y., Huang W.S., and Chen Y.H. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine (2008)
9. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 199 (2004) 201-216
10. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., and Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160 2 (1998) 870-876
11. Mahmood M.S., Siddique M., Hussain I., Khan A., and Mansoor M.K. Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide. Vaccine 24 22 (2006) 4838-4846
12. Mahmood M.S., Hussain I., Siddique M., Akhtar M., and Ali S. DNA vaccination with VP2 gene of very virulent infectious bursal disease virus (vvIBDV) delivered by transgenic E. coli DH5alpha given orally confers protective immune responses in chickens. Vaccine 25 44 (2007) 7629-7635
13. Eastcott J.W., Holmberg C.J., Dewhirst F.E., Esch T.R., Smith D.J., and Taubman M.A. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 19 13-14 (2001) 1636-1642
14. Moldoveanu Z., Love-Homan L., Huang W.Q., and Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 11-12 (1998) 1216-1224
15. Lopez A.M., Hecker R., Mutwiri G., van Drunen Littel-van den Hurk S., Babiuk L.A., and Townsend H.G. Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine. Vet Immunol Immunopathol 114 1-2 (2006) 103-110
16. Singh M., and O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 17 11 (1999) 1075-1081
17. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 169 1 (2002) 375-383
18. Arulanandam B.P., Mittler J.N., Lee W.T., O'Toole M., and Metzger D.W. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol 164 7 (2000) 3698-3704
19. Jegerlehner A., Schmitz N., Storni T., and Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172 9 (2004) 5598-5605